Biogen Suspends Apellis Trials After $5.6bn Deal, Stock Jumps 7%
BIIB•Biogen will suspend multiple Apellis Phase II trials and cut research staff following its $5.6bn acquisition, focusing development on the pegcetacoplan franchise. The stock also rallied 7% on heavy trading volume despite lower earnings estimate revision trends.
1. Acquisition Aftermath and R&D Reductions
Three months after completing its $5.6bn takeover of Apellis, Biogen has halted investment in the majority of the acquired company’s legacy research programmes and reduced a portion of the Apellis R&D team. Specific Phase II trials of pegcetacoplan in delayed graft function and focal segmental glomerulosclerosis have been listed as suspended due to strategic evaluation and recruitment challenges.
2. Strategic Focus on Pegcetacoplan Franchise
Biogen remains committed to its approved pegcetacoplan therapies—Empaveli for rare diseases and Syfovre for geographic atrophy—while shelving preclinical RNA, oral complement inhibitor and gene-edited assets from Apellis. Internal forecasts project the pegcetacoplan franchise to generate $785m in annual revenue by 2032.
3. Market Reaction and Analyst Outlook
Following the pipeline trimming announcement, Biogen’s shares surged 7% on above-average trading volume, though analysts caution that recent downward revisions to earnings estimates could temper further gains. Investors are weighing the near-term financial benefits of cost cuts against the potential loss of long-term innovation from the Apellis pipeline.
